Q3 2023 Results - Reimagining Medicine slide image

Q3 2023 Results - Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Other Financial review Conclusions Financial performance Immunology Neuroscience Ophthalmology Appendix Innovation: Clinical trials Oncology Global Health References Abbreviations Other 77 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation